Literature DB >> 21707553

Learning curve and pitfalls of a laparoscopic score to describe peritoneal carcinosis in advanced ovarian cancer.

Anna Fagotti1, Giuseppe Vizzielli, Barbara Costantini, Antonella Lecca, Valerio Gallotta, Maria Lucia Gagliardi, Giovanni Scambia, Francesco Fanfani.   

Abstract

OBJECTIVE: To prospectively estimate the agreement between a fellow in training in gynecologic oncology and a senior surgeon performing a laparoscopic score to describe peritoneal carcinosis diffusion in patients with advanced ovarian cancer.
DESIGN: Single-institutional non-inferiority trial.
SETTING: University hospital tertiary care center. POPULATION: Ninety consecutive patients with primary advanced ovarian cancer.
METHODS: The patients underwent staging-laparoscopy by a fellow in gynecologic oncology and a senior surgeon, sequentially and blindly. Single laparoscopic parameters (omental cake, peritoneal and diaphragmatic carcinosis, mesenteric retraction, bowel stomach infiltration, superficial liver metastasis) and a comprehensive laparoscopic score (PIV) were assessed in each procedure and registered. MAIN OUTCOME MEASURES: No differences in the score discriminating performance for predicting optimal cytoreduction were observed between fellows' and seniors' evaluations.
RESULTS: The median number of staging laparoscopies performed by each fellow was 30 (range 28-32). The median score was 6 (0-10) for the fellows and 6 (0-14) for senior surgeons (p=ns). Results were superimposable in 57 of 90 patients (63.3%). Dividing the study period into two blocks, cases 1-45 and cases 46-90, differences were equally distributed over time (16.6 vs. 20%; p=0.9). The area under the curve of the receiver operating characteristic (ROC) curves for the score of fellows and seniors was 0.86 and 0.89, respectively (p=ns).
CONCLUSIONS: The laparoscopic assessment of peritoneal cancer diffusion according to a laparoscopic score can reliably be carried out by a fellow in gynecologic oncology after 12 months' experience without significant differences from a senior surgeon's assessment.
© 2011 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2011 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2011        PMID: 21707553     DOI: 10.1111/j.1600-0412.2011.01227.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

Review 1.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

Review 2.  Prediction of optimal debulking surgery in ovarian cancer.

Authors:  Yong Jung Song
Journal:  Gland Surg       Date:  2021-03

Review 3.  The role of surgery in advanced epithelial ovarian cancer.

Authors:  María Martín-Cameán; Elsa Delgado-Sánchez; Antonio Piñera; Maria Dolores Diestro; Javier De Santiago; Ignacio Zapardiel
Journal:  Ecancermedicalscience       Date:  2016-08-17

4.  Port-Site Metastases and Chimney Effect of B-Ultrasound-Guided and Laparoscopically-Assisted Hyperthermic Intraperitoneal Perfusion Chemotherapy.

Authors:  Ming Chen Ba; Hui Long; Xiang Liang Zhang; Yuan Feng Gong; Zhao Fei Yan; Shuai Wang; Yun Qiang Tang; Shu Zhong Cui
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

5.  Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Shannon N Westin; Larissa A Meyer; Aaron Shafer; Jose Alejandro Rauh-Hain; Michaela Onstad; Lauren Cobb; Michael Bevers; Bryan M Fellman; Jennifer Burzawa; Priya Bhosale; Behrouz Zand; Amir Jazaeri; Charles Levenback; Robert L Coleman; Pamela T Soliman; Anil K Sood
Journal:  Int J Gynecol Cancer       Date:  2020-11-05       Impact factor: 3.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.